Bortezomib 100 mg | 98.00%
TargetMol

Bortezomib (PS-341) is a potent 20S proteasome inhibitor (Ki: 0.6 nM, in a cell-free assay).
More Information Supplier PageBortezomib (PS-341) is a potent 20S proteasome inhibitor (Ki: 0.6 nM, in a cell-free assay).
More Information Supplier PageRamatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.
More Information Supplier PageRamatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.
More Information Supplier PageRamatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.
More Information Supplier PageRamatroban (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.
More Information Supplier PageBortezomib (PS-341) is a potent 20S proteasome inhibitor (Ki: 0.6 nM, in a cell-free assay).
More Information Supplier PageNedaplatin is a derivative of cisplatin and DNA damage agent for tumor colony forming units (IC50: 94 μM). Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucleophilic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis […]
More Information Supplier PageLY303511, an inactive analogue of LY294002, is a mTOR inhibitor and no inhibition for PI3-K.
More Information Supplier Page